Meta-Analysis of the INSIG2 Association with Obesity Including 74,345 Individuals: Does Heterogeneity of Estimates Relate to Study Design? by Heid, Iris M. et al.
Meta-Analysis of the INSIG2 Association with Obesity
Including 74,345 Individuals: Does Heterogeneity of
Estimates Relate to Study Design?
Iris M. Heid
1,2.*, Cornelia Huth
1.,R u t hJ .F .L o o s
3, Florian Kronenberg
4,V e r aA d a m k o v a
5, Sonia S.
Anand
6, Kristin Ardlie
7, Heike Biebermann
8, Peter Bjerregaard
9, Heiner Boeing
10, Claude Bouchard
11,
Marina Ciullo
12,J a c k i eA .C o o p e r
13, Dolores Corella
14,15, Christian Dina
16,17, James C. Engert
18,E v a
Fisher
10, Francesc France `s
14,15, Philippe Froguel
16, Johannes Hebebrand
19,R o b e r tA .H e g e l e
20,A n k e
Hinney
19, Margret R. Hoehe
21,F r a n kB .H u
22,23,J a r o s l a vA .H u b a c e k
5,24,S t e v eE .H u m p h r i e s
13,
Steven C. Hunt
25, Thomas Illig
1,M a r j o - R i i t aJ a ¨rvelin
26,27,28, Marika Kaakinen
28, Barbara Kollerits
4,
Heiko Krude
8, Jitender Kumar
29, Leslie A. Lange
30, Birgit Langer
1, Shengxu Li
3, Andreas Luchner
31,
Helen N. Lyon
7,32, David Meyre
16, Karen L. Mohlke
30, Vincent Mooser
33,A l m u tN e b e l
34, Thuy Trang
Nguyen
35, Bernhard Paulweber
36,L o u i sP e r u s s e
37,L uQ i
21,22,T u o m oR a n k i n e n
11,D i e t e rR o s s k o p f
38,
Stefan Schreiber
34, Shantanu Sengupta
29, Rossella Sorice
12,A n i t aS u k
21, Gudmar Thorleifsson
39,
Unnur Thorsteinsdottir
39,40,H e n r yV o ¨lzke
41, Karani S. Vimaleswaran
3, Nicholas J. Wareham
3,D a w n
Waterworth
33, Salim Yusuf
6, Cecilia Lindgren
42,43, Mark I. McCarthy
42,43, Christoph Lange
44,J o e lN .
Hirschhorn
7,32,N a nL a i r d
44., H.-Erich Wichmann
1,45,46.
1Helmholtz Zentrum Mu ¨nchen, German Research Center for Environmental Health, Neuherberg, Germany, 2Department of Epidemiology and Preventive Medicine,
University Medical Center Regensburg, Regensburg, Germany, 3Medical Research Council Epidemiology Unit, Institute of Metabolic Science, Cambridge, United
Kingdom, 4Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Innsbruck, Austria,
5Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 6Department of Medicine and Clinical Epidemiology and Biostatistics, McMaster University,
Hamilton, Ontario, Canada, 7Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America, 8Charite ´ Campus Virchow Klinikum, Institut fu ¨r
Experimentelle Pa ¨diatrische Endokrinologie, Berlin, Germany, 9University of Southern Denmark, Copenhagen, Denmark, 10Department of Epidemiology, German
Institute of Human Nutrition Potsdam–Rehbru ¨cke, Nuthetal, Germany, 11Human Genomics Laboratory, Pennington Biomedical Research Center, Baton Rouge,
Louisiana, United States of America, 12Institute of Genetics and Biophysics ‘A.Buzzati-Traverso’, CNR, Naples, Italy, 13Centre for Cardiovascular Genetics, Royal Free
and University College Medical School, London, United Kingdom, 14Preventive Medicine Department, University of Valencia, Valencia, Spain, 15CIBER Fisiopatologı ´a
de la Obesidad y Nutricio ´n, Instituto de Salud Carlos III, Valencia, Spain, 16Pasteur Institute, CNRS 8090–Institute of Biology, Lille, France, 17Institut du Thorax, CNRS
ERL3147, INSERM U 915, Nantes, France, 18Departments of Medicine and Human Genetics, McGill University, Montre ´al, Que ´bec, Canada, 19Department of Child and
Adolescent Psychiatry, University of Duisburg–Essen, Essen, Germany, 20Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, 21Max
Planck Institut for Molecular Genetics, Berlin, Germany, 22Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, United States of America,
23Channing Laboratory, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 24Cardiovascular Research
Center, Prague, Czech Republic, 25Cardiovascular Genetics Division, University of Utah School of Medicine, Salt Lake City, Utah, United States of America,
26Department of Epidemiology and Public Health, Imperial College, London, United Kingdom, 27National Public Health Institute, Department of Child and
Adolescent Health, Oulu, Finland, 28Institute of Health Sciences and Biocenter Oulu, University of Oulu, Oulu, Finland, 29Institute of Genomics and Integrative
Biology, Delhi, India, 30Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America, 31Department of Internal
Medicine II, University Medical Center Regensburg, Regensburg, Germany, 32Children’s Hospital, Boston, Massachusetts, United States of America, 33Genetics
Division, Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America, 34Institute of Clinical Molecular Biology, Christian-Albrechts-
University of Kiel, Kiel, Germany, 35Institut fuer Medizinische Biometrie und Epidemiologie, Philipps-Universitaet Marburg, Marburg, Germany, 36F i r s tD e p a r t m e n to f
Internal Medicine, St. Johann Spital, Paracelsus Private Medical University Salzburg, Salzburg, Austria, 37Faculty of Medicine, Department of Social and Preventive
Medicine, Universite ´ Laval, Que ´bec, Que ´bec, Canada, 38Department of Pharmacology, Ernst Moritz Arndt University Greifswald, Greifswald, Germany, 39deCODE
genetics, Reykjavik, Iceland, 40Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 41Department of Community Medicine, Ernst Moritz Arndt University
Greifswald, Greifswald, Germany, 42Welcome Trust Center for Human Genetics, University of Oxford, Oxford, United Kingdom, 43Oxford Center of Diabetes,
Endocrinology and Metabolism, The Churchill Hospital, Headington, Oxford, United Kingdom, 44Department of Biostatistics, Harvard School of Public Health, Boston,
Massachusetts, United States of America, 45Chair of Epidemiology, Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universita ¨t,
Munich, Germany, 46Klinikum Grosshadern, Munich, Germany
PLoS Genetics | www.plosgenetics.org 1 October 2009 | Volume 5 | Issue 10 | e1000694Abstract
The INSIG2 rs7566605 polymorphism was identified for obesity (BMI$30 kg/m
2) in one of the first genome-wide association
studies, but replications were inconsistent. We collected statistics from 34 studies (n=74,345), including general population (GP)
studies, population-based studies with subjects selected for conditions related to a better health status (‘healthy population’, HP),
and obesity studies (OB). We tested five hypotheses to explore potential sources of heterogeneity. The meta-analysis of 27 studies
on Caucasian adults (n=66,213) combining the different study designs did not support overall association of the CC-genotype
with obesity, yielding an odds ratio (OR) of 1.05 (p-value=0.27). The I
2 measure of 41% (p-value=0.015) indicated between-study
heterogeneity. Restricting to GP studies resulted in a declined I
2 measure of 11% (p-value=0.33) and an OR of 1.10 (p-
value=0.015). Regarding the five hypotheses, our data showed (a) some difference between GP and HP studies (p-value=0.012)
and (b) an association in extreme comparisons (BMI$32.5, 35.0, 37.5, 40.0 kg/m
2 versus BMI,25 kg/m
2) yielding ORs of 1.16, 1.18,
1.22, or 1.27 (p-values 0.001 to 0.003), which was also underscored by significantly increased CC-genotype frequencies across BMI
categories (10.4% to 12.5%, p-value for trend=0.0002). We did not find evidence for differential ORs (c) among studies with higher
than average obesity prevalence compared to lower, (d) among studies with BMI assessment after the year 2000 compared to
those before, or (e) among studies from older populations compared to younger. Analysis of non-Caucasian adults (n=4889) or
children (n=3243) yielded ORs of 1.01 (p-value=0.94) or 1.15 (p-value=0.22), respectively. There was no evidence for overall
association of the rs7566605 polymorphism with obesity. Our data suggested an association with extreme degrees of obesity, and
consequently heterogeneous effects from different study designs may mask an underlying association when unaccounted for. The
importance of study design might be under-recognized in gene discovery and association replication so far.
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Introduction
One of the first genome-wide association (GWA) studies ever
and the first on obesity identified the INSIG2 gene represented by
the rs7566605 polymorphism as a novel gene for common obesity
[1]. Functional evidence depicted the INSIG2 gene from the very
start as an interesting candidate for obesity as being involved in the
reversed cholesterol transport by an interaction with sterol
regulatory element-binding proteins (SREBPs) [2], which are
transcription factors that activate the synthesis of cholesterol and
fatty acids in the liver and other organs [3].
The observed SNP-obesity-association was replicated in some,
but not in all studies [4–11]. A letter to Science by the authors of the
initial report in response to the emerging debate of the early
inconsistent results [1] raised the question of whether the
association might be more pronounced in studies that were not
ascertained for reasons related to better health status, when
comparing more severely obese subjects with normal controls, in
populations with a higher prevalence of obesity or in populations
with a higher mean age. The need for a meta-analysis was stated
there for the first time and re-stated by Lyon and colleagues [12].
Furthermore, a secular trend for increasing prevalence of obesity
was observed in two large population-based studies from the same
geographical region using the same protocols but one recruited
1994/95 (KORA-S3) and the other 1999–2001 (KORA-S4) [13].
The later study showed a stronger INSIG2-obesity-association
compared to the earlier study: This raised the additional question
whether the changes in nutritional intake and physical activity
[14,15] believed to contribute to the increase in the prevalence of
obesity during the last decades were the reason for some of the
between-study heterogeneity observed for this SNP’s association
with obesity.
The inconsistent reported associations and the many resulting
debates motivated us to undertake a systematic meta-analysis of all
available data to investigate potential causes of heterogeneity and
to look for consistent results among subgroups. It was thus the
specific aim of this meta-analysis to explore five hypotheses for
heterogeneity of the rs7566605 association with obesity: (Hypothesis
1) The association depends on study design. Therefore, we
classified studies as general population-based (GP) when they were
neither selected for any disease nor for not having any disease, as
any selection of this type was shown to potentially induce bias for
outcomes associated with the disease [16]. We classified studies as
‘healthy population’ (HP) when they were selected for reasons
related to a better health status (i.e. studies including subjects from
working populations or studies excluding subjects for with diseases
such as diagnosed type 2 diabetes), or obesity studies (OB) when
they were specifically designed to investigate obesity, usually case-
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ascertained for any disease to reduce overly complexity. (Hypothesis
2) The association is more pronounced when comparing more
extreme cases of obesity with normal or lean subjects, or (Hypothesis
3) among studies with a greater percentage of obese individuals.
(Hypothesis 4) The association is differentially seen in studies
including subjects with a higher age compared to studies based on
younger populations, or (Hypothesis 5) more pronounced in studies
with a more recent assessment of BMI (after year 2000) assuming
that these studies would reflect the changes in dietary habits and
physical activity of the last decade and assuming that subjects with
the INSIG2 risk genotype are more prone to gain weight in such an
environment.
Results
Data Collected
We have gathered data on 34 studies from across Europe, North
America, and Asia that met the inclusion criteria including a total
of 74,345 subjects. All studies were categorized a priori according to
their study design (GP, HP, OB), ethnicity, and whether it was
an adult or children population (Tables S1 and S2). A more
detailed description can be found in the original study publications
[1,4–12,17–20].
Main Analysis
The main results are summarized in Table 1: The meta-analysis
of 27 studies of Caucasian adults (n=66,213) showed a fixed effect
odds ratio (OR) of 1.076 (p-value=0.023) and a random effects
OR of 1.051 (p-value=0.268) with the I
2 measure indicating
significant between-study heterogeneity (I
2=41.0%, 95% confi-
dence interval, CI=[6.6%, 62.8%], Q-test p-value=0.015).
Some Heterogeneity Might Relate to Study Type
The I
2 measure declined (I
2=10.9%, 95% CI=[0.0%, 48.1%],
Q-test p-value=0.329) by restricting to the 16 GP studies,
including 48,844 subjects, yielding a fixed [random] effects OR
of 1.097 [1.092] (p-value=0.015 [0.035]). The OR estimates were
similar when excluding early published studies (p=0.054 [0.060]).
The I
2 measure for heterogeneity was zero among the five HP
studies, including 7640 subjects, and combined estimates yielded a
tendency towards a protective OR of 0.796 (p-value=0.028)
without remarkable change when excluding the early published
studies.
The OR among the sixOB studies,including 9729 subjects,of 1.152
using the random effect model was higher than the one for the GP
studies, but not statistically significantly different from unity (p-
value=0.253). There was substantial heterogeneity among the OB
studies (I
2=63.2%, Q-test p-value=0.018). The OR estimates were
similar when excluding the early published studies.
Author Summary
A polymorphism of the INSIG2 gene was identified as
being associated with obesity in one of the first genome-
wide association studies. However, this association has
since then been highly debated upon inconsistent
subsequent reports. We collected association information
from 34 studies including a total of 74,000 participants. In
a meta-analysis of the 27 studies including 66,000
Caucasian adults, we found no overall association of this
polymorphism rs7566605 with obesity, comparing sub-
jects with a body-mass-index (BMI)$30 kg/m
2 with normal
BMI subjects (BMI,30 kg/m
2). Our data suggested an
association of this polymorphism with extreme obesity
(e.g., BMI$37.5 kg/m
2) compared to normal controls. Such
an association with extreme obesity might induce
heterogeneous effects from different study designs
depending on the proportion of extreme obesity included
by the design. However, further studies would be required
to substantiate this finding. The importance of study
design might be under-recognized in gene discovery and
association replication so far.
Table 1. Main meta-analysis results of the INSIG2 rs7566605 association with obesity.
# cases/controls
(# studies)
OR (p-value)
fixed effect
OR (p-value)
random effect I
2 (p-value)
P-value test for difference of
fixed [random] effect ORs
b
All-CA 16,365/49,848 (27) 1.076 (0.023) 1.051 (0.268) 41.0 (0.015)
All-CA
a 10,761/30,168 (19) 1.077 (0.074) 1.054 (0.361) 36.4 (0.057)
GP 9162/39,682 (16) 1.097 (0.015) 1.092 (0.035) 10.9 (0.329) GP vs HP: 0.004 [0.005]
GP
a 5803/23,243 (12) 1.100 (0.054) 1.080 (0.060) 1.3 (0.431) GP
a vs HP
a: 0.038 [0.089]
HP 1307/6333 (5) 0.796 (0.028) 0.796 (0.028) 0.0 (0.415) HP vs OB: 0.038 [0.022]
HP
a 795/4116 (3) 0.821 (0.135) 0.772 (0.198) 46.2 (0.156) HP
a vs OB
a:0.038 [0.109]
OB 5896/3833 (6) 1.163 (0.018) 1.152 (0.253) 63.2 (0.018) OB vs GP: 0.478 [0.680]
OB
a 3119/2338 (4) 1.155 (0.144) 1.179 (0.337) 65.0 (0.036) OB
a vs GP
a: 0.657 [0.693]
ALL-NC 553/4336 (4) 1.013 (0.936) 0.945 (0.818) 43.5 (0.150)
ALL-CH 1802/1441 (3) 1.147 (0.216) 1.147 (0.216) 0.0 (0.830)
Pooled association for all Caucasian adult studies combined (All-CA) as well as stratified by study type (GP=general population, HP=healthy population, OB=obesity
study), for all non-Caucasian studies (All-NC), or the children studies (All-CH) indicating differential results among GP or HP studies (Hypothesis 1). Numbers stated are
the number of obese (BMI$30 kg/m
2, ‘cases’) and non-obese (BMI,30 kg/m
2, ‘controls’) subjects with the number of studies, the recessive model ORs (p-value)
comparing the odds for obesity among the subjects with the CC genotype versus subjects with the CG or GG genotype using fixed or random effects models, the I
2
measure (p-value of the Q-statistics), and the p-value testing for pair-wise difference between GP, HP, and OB studies.
aExcluding studies published before the response letter in Science by Herbert et al., December 2006 [1], in which the hypothesis of potential heterogeneity due to study
design and a first call for this meta-analysis were stated (i.e., excluding American_Polish, NHS, KORA_S4, Essen_trios, EPIC_Norfolk, MRC_Ely, DESIR, SHIP, OB_adult).
bP-values corrected for pair-wise comparison of three subgroups need to be multiplied by three.
OR=Odds Ratios.
doi:10.1371/journal.pgen.1000694.t001
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PLoS Genetics | www.plosgenetics.org 3 October 2009 | Volume 5 | Issue 10 | e1000694Figure 1A–1C shows forest plots of the Caucasian adult studies
with combined estimates by study type. The p-value testing for
difference between the GP and the HP combined estimates was
0.004 [0.012 when corrected for pair-wise testing of three
subgroups] and 0.039 [0.089] when excluding the early published
studies. Thus, there is some, but not completely conclusive
evidence for Hypothesis 1 that study design might explain some of
the between-study heterogeneity of this genetic association.
Studies in Non-Caucasian Adults or Children
In the pooled analysis of the four studies on non-Caucasian
adults (n=4889), we found no significant association of the CC
genotype with obesity. The pooled analysis of the three pediatric
studies (n=3243) was also not significant (Table 1, Figure 1D and
1E).
Increasing Strength of Association in More Extreme
Comparisons
Our data suggested an association with increased ORs among
the Caucasian adults when more extremely obese subjects were
compared to lean controls (Table S3; Hypothesis 2): combining over
all studies, the ORs gradually increased from 1.156 to 1.183,
1.221, or 1.265 (p-values ranging from 0.001 to 0.003) when
moving the BMI cut-off for the obese cases from 32.5 to 35.0, 37.5
or 40.0 kg/m
2, respectively, and comparing to controls with
BMI,25 kg/m
2. A similar trend for increasing ORs was seen
when comparing extremely obese subjects against controls with
BMI,30 kg/m
2 or BMI,20.0 kg/m
2. Among the GP studies, the
ORs increased from 1.198 to 1.257, 1.313, or 1.414 (p-values
ranging from 0.001 to 0.003), respectively. The analogous
comparison for HP studies revealed that the protective influence
of the CC homozygous was reversed in the more extreme
comparisons with ORs from 0.856 to 0.959, 1.139, or 1.604. For
the OB studies, the ORs of the analogous comparisons were well
above unity for all comparisons, but did not show a trend.
As summarized in Table 2, the accompanying trend analyses of
the CC genotype frequencies across the various BMI categories
indicated significantly increased CC genotype frequencies from
10.4% to 12.5% (p-value testing for trend=0.0002), which
persisted when excluding the early published studies (p-val-
ue=0.0008). A similar trend was seen among GP studies.
In both types of analyses, the varying cut-point ORs as well as
the trend in genotype frequencies by BMI categories, suggest an
association of the rs7566605 with extreme obesity compared to
normal controls (Hypothesis 2).
Further Hypotheses on Potential Sources of
Heterogeneity
Table 3 summarizes the results of the further three hypotheses
to explain heterogeneity, which were tested for the Caucasian
adult studies. Hypothesis 3: there was some tendency towards higher
ORs among ‘more obese’ study populations compared to the ‘less
obese’ study populations (p-value=0.052 [0.285] testing for
difference of the fixed [random] effects ORs), but not statistically
significant. Hypothesis 4: there was no evidence for any difference
between studies from older populations (i.e. mean age of subjects
above 50 years) as compared to studies from younger populations
(i.e. mean age below 50 years). Hypothesis 5: there was a tendency
towards more pronounced ORs for the studies with BMI assessed
after the year 2000 as compared to studies with BMI assessed
before 2000 (p-value=0.007 [0.095]), but not statistically
significant given the various tests performed and particularly not
when excluding the early published studies (p-value=0.086
[0.248]). Hypotheses 3–5 were not tested in the HP or OB stratified
analyses as too few (3–6) studies were available.
Sensitivity Analyses
The sensitivity analyses (Table S4) indicated robustness of
estimates towards selection of gender or age and no significant
difference between published and unpublished studies. Excluding
the two studies with self-reported BMI from the overall GP meta-
analysis resulted in a slight increase of the OR estimate.
Genetic Model
We specifically examined the association under the recessive
genetic model as suggested by the original paper [1]. Our data
on the raw numbers of obese or non-obese subjects with one of
the three genotypes underscored a recessive model in the
Caucasian adult studies combined (ORCCversusGG=1.112 [1.029,
1.203], p-value=0.007, and ORGCversusGG=0.988 [0.940, 1.037],
p-value=0.618) as well as among the GP studies
(ORCCversusGG=1.076 [0.976, 1.185], p-value=0.142, and
ORGCversusGG=0.995 [0.956, 1.036], p-value=0.813).
Secondary Analyses on BMI as a Quantitative Outcome
The secondary analyses on BMI as a quantitative outcome were
only performed in GP and HP studies. These analyses generally
showed results consistent with the obesity analyses, but less, if any,
significance (Figure S1, Tables S5, S6, and S7).
Discussion
We conducted a systematic meta-analysis on published and
unpublished studies by collecting summary statistics on the
association of the rs7566605 SNP near the INSIG2 gene using a
recessive genetic model as proposed by Herbert and colleagues.
This SNP was highly debated and the inconsistent findings were
very much puzzling underscored by again inconclusive findings in
two recent publications [21,22]. To solve this puzzle, we collected
aggregated study-specific data from 34 studies with a total of
74,345 subjects analyzed according to a standardized model.
The main analysis did not support evidence for an overall
association with obesity of the CC-genotype compared to the CG/
GG (OR=1.05, p-value=0.268). Our data suggested an associ-
ation for more extreme obese subjects (BMI$32.5, 35.0, 37.5,
40.0 kg/m
2) compared to normal controls (BMI,25 kg/m
2) with
ORs increasing to 1.16, 1.18, 1.22, 1.27 (p-values between 0.001
and 0.003) and significantly increased CC-genotype frequencies
with increasingly high BMI categories (10.4% to 12.5%, p-value
for trend=0.0002).
The main analysis pointed towards significant between-study
heterogeneity with an I
2 measure of 41%. When we restricted the
analysis to GP studies, the I
2 declined to 11% and the OR
increased to 1.10. This is in-line with a very recently published
study, which found the OR to increase from 1.02 for a combined
analysis of diverse types of studies including 16,781 subjects to an
OR of 1.15 when restricting to the general population-based
INTER99 cohort including 6,158 subjects [21]. This was the
largest GP study on this SNP-association prior to this meta-
analysis.
The Degree of Obesity and the Study Design as a
Potential Source of Heterogeneity
The results of our analyses suggest an association of this SNP
with extremely obese subjects compared to normal controls, but
future research will need to confirm this finding. Study design can
impact how many extremely obese subjects are included in the
Meta-Analysis on the INSIG2 rs7566605 with Obesity
PLoS Genetics | www.plosgenetics.org 4 October 2009 | Volume 5 | Issue 10 | e1000694Figure 1. Forest plot on Odds Ratio estimates of the INSIG2 rs7566605 association with obesity. Association with obesity (BMI $ 30 kg/
m
2) for (A) the Caucasian adult general population-based (GP) studies, (B) the Caucasian adult studies ascertained for reasons related to health status
(HP), (C) the Caucasian adult obesity case-control studies (OB), (D) the non-Caucasian adult studies, and (E) the pediatric studies. Shown are recessive
model OR estimates comparing the CC genotype versus CG or GG for each study and pooled estimates. The fixed effect (FE) model OR is shown in
case of no significant heterogeneity as tested by the Q-statistics; a random effect (RE) model is shown otherwise.
doi:10.1371/journal.pgen.1000694.g001
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will have greater power to detect the association, while study
designs that sample fewer of these subjects will have little power to
detect the association. An association with extreme obesity might
well be masked by study design, and meta-analyses which
disregard study design differences.
The tendency of higher OR estimates observed in the general
population-based studies (GP) and the obesity case-control studies
compared to ‘healthy population’ (HP) studies could possibly
reflect the association for extreme obesity compared to normal
controls. We have classified studies as ‘ascertained for criteria
related to a better health status’ (‘HP’) when patient groups were
excluded or when the sample was ascertained based on working
populations, which are known to be usually more healthy. We
have performed this classification blinded for the study estimate to
exclude bias from informative misclassification. It could be that the
common rs7566605 directly or via tagging another possibly rare
and quite penetrant variant does not so much alter BMI
throughout the distribution, but really puts participants into the
very obese category. Thus an effect is picked up in the GP samples,
but not in the HP studies with fewer extremely obese persons. This
would also be in-line with (i) our more pronounced findings in the
studies with a higher percentage of obese subjects, and (ii) the lack
of association in the quantitative BMI-analysis, which tests for a
shift in the full BMI distribution.
It could also be hypothesized that the between-study heteroge-
neity is due to an interaction of the gene with the environment of
high fat diet: INSIG2 is regulated by atherogenic diet and oxidized
oil in rodents [23,24] and such a diet relates to higher obesity
status. A gene-environment interaction was also suggested by
reports that life-style interventions including physical training have
less positive effects in CC genotype carriers than in CG/GG
subjects [25–27]. A person at the brink of getting obese might
either comply to exercise and avoid becoming obese or might give
up and end in the extreme obesity category. This would be in-line
with our pronounced findings for more extreme degrees of obesity.
It might also be speculated that our more pronounced association
among studies with BMI assessment after the year 2000 compared
to before 2000 reflects this gene-environment interaction as well:
assuming that a change in nutritional habits and physical activity
contributed to the increase in obesity observed in the last decades,
the studies with a more recent BMI assessment might reflect this
more ‘‘modern’’ environment and the INSIG2-obesity association
would emerge here more clearly.
Also, unknown epistatic interaction of the rs7566605 with one
or other (rare) polymorphisms could lead to association with the
more extreme obesity phenotype, with the INSIG2 gene being part
of a complex that functions as a biological entity (SREBP, SCAP,
INSIG2).
The importance of ascertainment of the study sample might be
under-recognized so far. Monsees and colleagues [16] have
illustrated that ascertaining for or against disease would induce a
bias in genetic association estimates when the genetic marker as
well as the phenotype under study (here obesity) are associated
with the disease. As obesity is associated with many chronic
diseases such as type 2 diabetes and cardiovascular disease,
exclusion of such study participants opens up for bias, if
association of the SNP with the disease cannot be precluded.
We had specifically excluded studies ascertained for disease and
had also planned on separating HP from GP studies ahead of the
analyses. We would like to highlight that we have adopted a very
strict definition of GP and that there might be special advantages
Table 2. Comparing more extreme degrees of obesity.
BMI (kg/m
2) ,20 20–25 25–30 30–32.5 32.5–35 35–37.5 37.5–40 .40 P-value
b
All-CA %CC 10.4 10.7 10.5 10.5 11.9 11.2 12.0 12.5 0.0002
N 66,213 3314 22462 23072 5869 3578 2150 1404 3364
All-CA
a %CC 9.9 10.8 10.9 10.8 11.6 12.0 12.1 12.7 0.0008
N 39,414 2321 13671 3447 1962 1962 1162 829 2317
GP %CC 10.7 10.8 10.2 10.4 12.0 12.4 12.6 13.5 0.007
N 48,844 2490 18551 18641 4300 2299 1111 620 832
GP
a %CC 10.6 10.8 10.8 10.7 12.01 12.9 12.1 13.7 0.005
N 29,046 1684 10975 10584 2546 1432 727 421 677
HP %CC 10.6 10.4 11.9 9.7 8.1 7.5 13.0 8.6 0.345
N 7640 273 2772 3288 679 323 147 77 81
HP
a %CC 8.3 10.1 11.8 10.1 7.0 9.6 17.6 2.9 0.758
N 4911 121 1716 2279 457 186 83 34 35
OB %CC 8.5 10.3 10.8 11.8 13.1 10.3 11.3 12.4 0.009
N 9729 551 2139 1143 890 956 892 707 2451
OB
a %CC 8.1 11.9 10.0 12.4 12.2 10.8 11.5 12.4 0.054
N 5457 516 980 842 444 344 352 374 1605
The data suggest an association when comparing more extreme degrees of obesity with normal controls, which is a potential explanation for the heterogeneity of the
INSIG2 rs7566605 association with obesity (Hypothesis 2). Numbers stated are frequencies of risk genotype CC (C being the minor allele) across BMI categories for the
Caucasian adult studies combined (All-CA) as well as stratified by study type (GP=general population, HP=healthy population, OB=obesity study). Also given are the
p-values from testing for a trend of genotype frequencies across categories. (Not for All-NC or All-CH due to the few subjects in each category.)
aExcluding studies published before the response letter by Herbert et al., December 2006 [1] in which the hypothesis of potential heterogeneity due to study design
and a first call for this meta-analysis were stated (i.e., excluding American_Polish, NHS, KORA_S4, Essen_trios, EPIC_Norfolk, MRC_Ely, DESIR, SHIP, OB_adult, which are
all Caucasian studies).
bP-value testing for a trend across the BMI categories.
doi:10.1371/journal.pgen.1000694.t002
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healthy samples in other instances [29].
Strengths and Limitations of This Study
This meta-analysis has several strengths: (1) We have conducted
a systematic approach by collecting all studies published before
January 1, 2008, including seven studies that were unpublished at
that time. (2) The meta-analysis is large including a total of 74,365
subjects. (3) We separated working tasks, with one researcher
designing the analysis plan, recruiting studies, classifying studies by
study type, and deciding upon compliance to inclusion criteria,
while the other cared for the incoming data and performed the
analysis. Therefore, design decisions were made in a blinded way,
which guarded against subtle post-hoc data-driven analysis
decisions, study selection bias, and informative misclassification
of study design. (4) We collected data according to a strict protocol
including standardized analysis from each study partner, with
strong quality control of study-specific results. (5) We performed
only a limited number of pre-defined subgroup analyses with some
amendment during the review process. (6) We had a strong focus
on the diversity of study design, which is unique in genetic
epidemiological research at the time being and an issue probably
under-recognized so far.
It might be considered a disadvantage that we did not include
studies with subjects selected for diseases, particularly those
associated with type 2 diabetes and thus a higher prevalence of
obesity, as the association might be stronger in such studies. This
might have been one reason for the initial investigation by Herbert
and colleagues to detect this association, as mostly type 2 diabetes
or asthma ascertained samples had been used. However, we
excluded these samples by design in order to reduce heterogeneity
and to reduce the influence of counter-regulating disease processes
or medications. Furthermore, publication bias is always a threat
for meta-analyses as the extent and direction of this selection
cannot fully be determined; we attempted to guard against this by
recruiting also unpublished studies. It might be considered a
further disadvantage that our hypotheses were motivated by the
early published studies, which are included in this meta-analysis; to
accommodate for this fact, we repeated all analyses excluding
these studies (see Text S1D). Finally, it might be considered a
Table 3. Exploring potential sources of heterogeneity for the INSIG2 rs7566605 association with obesity (Hypotheses 3–5).
Group
# subjects
(# studies)
OR (p-value)
fixed effect
OR (p-value)
random effect I
2 (p-value)
Testing for
difference p-value
e
% obese $18%
a All-CA 34,999 (17) 1.127 (0.003) 1.083 (0.223) 55.0 (0.003)
All-CA
d 20,882 (12) 1.108 (0.049) 1.069 (0.444) 54.0 (0.013)
GP 21,394 (8) 1.175 (0.002) 1.164 (0.013) 21.2 (0.261)
GP
d 13,232 (6) 1.139 (0.044) 1.113 (0.251) 33.3 (0.186)
% obese ,18%
a All-CA 31,214 (10) 0.989 (0.841) 0.989 (0.841) 0.0 (0.856) 0.052 [0.285]
All-CA
d 18,532 (7) 1.024 (0.737) 1.024 (0.737) 0.0 (0.731) 0.368 [0.699]
GP 27,450 (8) 1.006 (0.912) 1.006 (0.912) 0.0 (0.792) 0.044 [0.083]
GP
d 15,814 (6) 1.048 (0.539) 1.048 (0.539) 0.0 (0.709) 0.401 [0.615]
Mean age $50 years
b All-CA 28,807 (11) 1.098 (0.059) 1.056 (0.464) 41.9 (0.070)
All-CA
d 17,635 (8) 1.110 (0.094) 1.068 (0.432) 25.1 (0.228)
GP 19,953 (7) 1.131 (0.041) 1.120 (0.114) 14.1 (0.322)
GP
d 13,221 (6) 1.181 (0.017) 1.169 (0.054) 9.0 (0.358)
Mean age ,50 years
b All-CA 37,406 (16) 1.060 (0.166) 1.047 (0.442) 43.6 (0.032) 0.593 [0.929]
All-CA
d 21,779 (11) 1.051 (0.375) 1.050 (0.549) 46.2 (0.046) 0.521 [0.881]
GP 28,891 (9) 1.074 (0.146) 1.071 (0.204) 14.9 (0.310) 0.505 [0.621]
GP
d 15,825 (6) 1.025 (0.728) 1.025 (0.728) 0.0 (0.613) 0.149 [0.217]
BMI after/during 2000
c All-CA 28,810 (14) 1.172 (0.0004) 1.135 (0.071) 47.5 (0.025)
All-CA
d 20,374 (11) 1.145 (0.014) 1.119 (0.164) 38.9 (0.089)
GP 17,217 (7) 1.218 (0.001) 1.216 (0.002) 3.9 (0.396)
GP
d 13,221 (6) 1.181 (0.017) 1.169 (0.054) 9.0 (0.358)
BMI before year 2000
c All-CA 37,403 (13) 0.987 (0.771) 0.986 (0.767) 1.5 (0.431) 0.007 [0.095]
All-CA
d 19,040 (8) 0.990 (0.875) 0.984 (0.836) 22.5 (0.250) 0.086 [0.248]
GP 27,450 (8) 1.021 (0.676) 1.021 (0.676) 0.0 (0.713) 0.023 [0.029]
GP
d 15,825 (6) 1.025 (0.728) 1.025 (0.728) 0.0 (0.613) 0.149 [0.217]
Stated values are ORs (p-values) based on fixed or random effects models and measures of I
2 (p-value from Q statistics) for each group and p-values testing for
difference between ORs of the two corresponding groups. (Not for HP, OB, NC, or CH studies due to the few number of studies.)
aStudies with percentage of subjects with BMI $30$18% or ,18%.
bStudies with mean age $50 years or ,50 years.
cStudies with BMI assessment after/during year 2000 or before year 2000.
dExcluding studies published before the response letter by Herbert et al., December 2006 [1], in which the hypothesis of potential heterogeneity due to study design
and a first call for a meta-analysis were stated (i.e. excluding American_Polish, NHS, KORA-S4, Essen_trios, EPIC_Norfolk, MRC_Ely, DESIR, SHIP, OB_adult).
eTesting for difference of fixed effect OR [random effects OR].
OR=Odds Ratio, All-CA=all Caucasian adult studies combined, GP=general population studies.
doi:10.1371/journal.pgen.1000694.t003
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Caucasian adult or children studies for a conclusive comparison
with the Caucasian adult studies.
Conclusions
This pooled analysis including all study designs does not provide
evidence for overall association of the INSIG2 rs7566605 CC
genotype with increased risk of obesity compared to the CG or
GG genotypes. Our data suggest an association with extreme
degrees of obesity and consequently heterogeneous effects from
different study designs may mask an underlying association when
unaccounted for. The importance of study design might be under-
recognized in gene discovery and association replication so far.
Materials and Methods
Meta-Analysis Concept
We designed our meta-analysis as a pooled analysis of study-
specific association estimates according to a standardized protocol
(see ‘data form’, Text S1B, and pre-defined analysis plan, Text
S1C) with an amendment added during the review process (Text
S1D).
Our eligibility criteria for studies were (i) data available on BMI,
the INSIG2 rs7566605 SNP genotypes, age and sex, (ii) sample size
of at least 200 subjects, (iii) ethical approval, and (iv) either general
population-based (GP), ascertained for reasons related to a better
health status such as studies including only subjects in the work-
force or studies excluding subjects with diseases (‘healthy
population’, HP), or designed specifically to study obesity such
as obesity case-control or obesity family studies (OB). We excluded
all studies selecting subjects for any disease. For more information
on the classification of studies by study type, see Text S1E. We did
not exclude on any age or ethnicity criteria to allow exploration of
potential heterogeneity. We controlled for study selection bias by
separating the two main tasks between the two first authors: IMH.
took care of study recruitment, compliance to inclusion criteria,
and classification of studies by study type, and CH performed
quality control and statistical analysis.
Study Recruitment, Collection of Aggregated Data, and
Quality Control
We identified all eligible studies published before January 1,
2008 by a systematic PubMed literature search using the search
terms ‘INSIG2’ OR ‘INSIG-2’ OR ‘rs7566605’. Additionally we
identified unpublished studies through contacting researchers in
the field by making a call for this meta-analysis in several consortia
(GIANT, KORA-500K, IL-6-consortium), in the letter to Science
by Herbert and colleagues [1], in the paper by Lyon and
colleagues [12], and in meeting presentations. We sent out and
collected standardized data forms, and verified all entries for
within-plausibility as well as consistency with publications, if
available. We made plausibility checks by use of double
information in the aggregated data. All study-specific ambiguities
were clarified with the respective study investigators.
All involved studies were conducted according to the principles
expressed in the Declaration of Helsinki. The studies were
approved by the local Review Boards. All study participants
provided written informed consent for the collection of samples
and subsequent analysis.
Statistical Analysis
For each study, OR estimates comparing the odds of obesity
(BMI$30 kg/m
2) for subjects with the minor-allele homozygous
genotype (CC) with subjects of the other genotypes combined (CG,
GG), thus assuming a recessive model, were calculated using
logistic regression adjusting for age and sex. We also collected OR
estimates with standard errors (SE) for the odds of more extreme
degrees of obesity (i.e. subjects with BMI$32.5, 35.0, 37.5, or
40.0 kg/m
2) compared to various degrees of leanness (i.e. subjects
with BMI,30, 25, or 20 kg/m
2). Furthermore, we collected
summary statistics (mean and SE) on the difference in mean BMI
between subjects with the CC genotype compared to subjects with
the CG or GG genotypes using linear regression adjusted for age
and sex. For each study, analyses stratified for sex or age (with a
cut-off at 50 years) were performed as well. Among the six studies
from non-Caucasian populations, two studies had too few (,3)
subjects among the obese with the CC genotype to be included
into the dichotomous obesity analysis, while they were included for
the quantitative BMI analysis.
For the meta-analysis, we combined beta-estimates among
Caucasian adult studies (All-CA) followed by a stratified analysis
by study type (GP, HP, OB) and combined estimates among non-
Caucasian (All-NC) or children studies (All-CH), see ‘amendment
to analysis plan’, Text S1D.
The following was only performed on Caucasian adults as the
number of available non-Caucasians or children was too low. We
tested for differential association between the GP, HP, or OB
studies applying a t-test on the combined beta-estimates and
correcting p-values for testing three subgroups. We tested for a
trend in CC genotype frequencies across the different BMI
categories and tested for differential associations separating the
studies for higher or lower obesity prevalence, higher or lower
mean age of study subjects, or for a more or less recent BMI
assessment using a t-test on the combined beta-estimates. This was
complemented by sensitivity analyses stratifying on sex, age,
publication status, and type of BMI assessment. As the hypotheses
were motivated by the early published studies mentioned in the
letter to Science by Herbert and colleagues [1], we repeated all
analyses with exclusion of these hypotheses-generating studies.
In all analyses, between-study heterogeneity was tested by the
x
2-based Q-statistic and quantified by I
2 as a measure of the
proportion of variance between the study-specific estimates that is
attributable to between-study difference rather than random
variation. We pooled study-specific estimates according to the
inverse-variance weighted fixed effect or the DerSimonian and
Laird random effects model [30]. Heterogeneity was considered to
be significant at the 10% level. All statistical analyses were
performed with SAS (statistical analysis software, SAS institute,
Inc.). Forest plots were prepared using Review Manager software
(Cochrane Collaboration, Copenhagen, DK).
Supporting Information
Figure S1 Forest plot on estimates of the INSIG2 rs7566605
association with BMI. Association of the INSIG2 SNP with BMI
for (A) the Caucasian adult general-population based studies (GP),
(B) the Caucasian adult studies selected for healthy population
(HP), (C) the Non-Caucasian adult studies, (D) the pediatric
studies. Shown are recessive model beta estimates comparing the
CC genotype versus CG or GG for each study and pooled
estimates. The fixed effect (FE) model beta is shown in case of no
significant heterogeneity as tested by the Q-statistics; a random
effect (RE) model is shown otherwise.
Found at: doi:10.1371/journal.pgen.1000694.s001 (0.44 MB TIF)
Table S1 Characterization of eligible and recruited studies.
Found at: doi:10.1371/journal.pgen.1000694.s002 (0.12 MB
DOC)
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Found at: doi:10.1371/journal.pgen.1000694.s003 (0.20 MB
DOC)
Table S3 Stronger genetic effects when comparing more
extreme degrees of obesity as an explanation of the heterogeneity
of the INSIG2 rs7566605 association (Hypothesis 2). Pooled
association estimates for increasing degrees of obesity for all
Caucasian adult studies combined (All-CA) as well as stratified by
study type (GP=general population, HP=healthy population,
OB=obesity study), for all Non-Caucasian studies (All-NC), but
not for children studies due to non-comparability of BMI
categories. Numbers stated are ORs comparing cases versus
controls (p-values) from the pooled analysis (fixed and random
effects), number of cases/controls (number of pooled studies), and
the I
2 (p-value from Q statistics).
Found at: doi:10.1371/journal.pgen.1000694.s004 (0.07 MB
DOC)
Table S4 Sensitivity analyses for the association of the INSIG2
SNP with obesity regarding sex, age, published or unpublished
status of studies, self-reported or measured BMI. Stated values are
ORs (p-values) based on fixed or random effects models, the I
2 (p-
value of Q test) for each group, and p-values testing for difference
between the fixed effect [random effect] ORs of the two
corresponding groups. (Not for HP, OB, All-NC, or All-CH due
to low numbers of studies.)
Found at: doi:10.1371/journal.pgen.1000694.s005 (0.07 MB
DOC)
Table S5 Main results of pooled association of the INSIG2 SNP
with body-mass-index (BMI). The analyses for all Caucasian adult
studies combined (All-CA) as well as stratified by study type
(GP=general population, HP=healthy population, OB=obesity
study), for all Non-Caucasian studies (All-NC), and for the children
studies (All-CH) indicated some difference between GP and HP
studies (Hypothesis 1). Numbers stated are recessive model beta-
estimates (p-values), i.e., mean difference of BMI between subjects
with the CC genotype compared to subjects with the CG or GG
genotype, using fixed or random effects models, the I
2 (p-value of
Q-statistics), and p-values testing for pair-wise difference between
GP, HP, or OB studies.
Found at: doi:10.1371/journal.pgen.1000694.s006 (0.04 MB
DOC)
Table S6 Exploring potential sources of heterogeneity of the
INSIG2 rs7566605 association with BMI (Hypotheses 3–5). Stated
values are pooled beta-estimates (p-values) based on fixed or
random effects model, I
2 (p-values of Q-test) for each group, and
p-values testing for difference between the beta-estimates of the
two corresponding groups. (Not for HP, NC, or CH due to low
numbers of studies.)
Found at: doi:10.1371/journal.pgen.1000694.s007 (0.08 MB
DOC)
Table S7 Sensitivity analyses for the association of the INSIG2
SNP with BMI regarding sex, age, published status, or self-
reported or measured BMI. Stated values are beta-estimates (p-
values) based on fixed and random effects models, I
2 (p-value of Q
test) for each group, and p-values testing for difference between the
beta-estimates of the two groups. (Not for HP, All-NC, or All-CH
due to low numbers of studies.)
Found at: doi:10.1371/journal.pgen.1000694.s008 (0.07 MB
DOC)
Text S1 References of included published studies; data form sent
to each study partner; predefined analysis plan; amendment to
analysis plan; and classification of studies due by study type.
Found at: doi:10.1371/journal.pgen.1000694.s009 (0.18 MB
DOC)
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